- Home
- FRBA vs IGMS Comparison
FRBA vs IGMS Comparison
Compare FRBA & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRBA
- IGMS
- Stock Information
- Founded
- FRBA 2007
- IGMS 1993
- Country
- FRBA United States
- IGMS United States
- Employees
- FRBA N/A
- IGMS N/A
- Industry
- FRBA Major Banks
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- FRBA Finance
- IGMS Health Care
- Exchange
- FRBA Nasdaq
- IGMS Nasdaq
- Market Cap
- FRBA 377.1M
- IGMS 82.1M
- IPO Year
- FRBA N/A
- IGMS 2019
- Fundamental
- Price
- FRBA $14.57
- IGMS $1.30
- Analyst Decision
- FRBA Buy
- IGMS Hold
- Analyst Count
- FRBA 1
- IGMS 8
- Target Price
- FRBA $17.00
- IGMS $6.14
- AVG Volume (30 Days)
- FRBA 50.0K
- IGMS 225.7K
- Earning Date
- FRBA 04-21-2025
- IGMS 03-06-2025
- Dividend Yield
- FRBA 1.64%
- IGMS N/A
- EPS Growth
- FRBA 75.79
- IGMS N/A
- EPS
- FRBA 1.67
- IGMS N/A
- Revenue
- FRBA $128,676,000.00
- IGMS $2,679,000.00
- Revenue This Year
- FRBA $3.24
- IGMS $134.71
- Revenue Next Year
- FRBA $6.26
- IGMS $74.27
- P/E Ratio
- FRBA $8.64
- IGMS N/A
- Revenue Growth
- FRBA 34.24
- IGMS 25.77
- 52 Week Low
- FRBA $11.20
- IGMS $1.19
- 52 Week High
- FRBA $15.87
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- FRBA 40.85
- IGMS 35.33
- Support Level
- FRBA $14.30
- IGMS $1.26
- Resistance Level
- FRBA $14.71
- IGMS $1.43
- Average True Range (ATR)
- FRBA 0.32
- IGMS 0.11
- MACD
- FRBA -0.09
- IGMS 0.11
- Stochastic Oscillator
- FRBA 17.46
- IGMS 80.24
About FRBA First Bank
First Bank is a full-service commercial bank, with an emphasis on providing personal and business financial services to individuals and small to mid-sized businesses. The Bank provides its customers with a variety of financial services targeting all segments of the retail and corporate market. Its Business Banking offers commercial deposit accounts, business loans, online banking, and cash management.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.